GoTrust Idem Key is the first FIDO Security Key able to access MojeID’s Czech government and high assurance EU eIDAS services
26.7.2022 10:00:00 EEST | Business Wire | Press release
Today, GoTrustID Inc. (GoTrust) announced that their Idem Keys with FIDO2 Security Level 2 certification are being used in the Czech Republic by CZ.NIC’s MojeID service to provide the highest level of eIDAS assurance for digital transactions throughout the entire EU. MojeID became the first eIDAS approved eID service that leverages the FIDO standards and certification program. This is a remarkable milestone that benefits Czech citizens by letting them utilize phishing resistant technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220726005092/en/
GoTrust Idem Key - FIDO2 Security Level 2 USB/NFC Security Key (Graphic: Business Wire)
As the Idem Keys are qualified to the top assurance level they can also be used for lower-level assurances, meaning that Idem Keys can access any type of eIDAS transaction. The GoTrust Idem keys have USB-A, USB-C and NFC interfaces. All Idem Keys work with Windows, MAC, Chromebook, iOS and Android phones. The iPhone and Android phone are supported using the NFC interface and as a bonus the Idem Key can be used for physical access in commercial environments. Idem Keys are waterproof with IP68 rating and are available from the top 2 online stores in the Czech Republic.
The benefit of using the FIDO standard is that the Idem Keys work with any web-based services, anywhere without downloading a driver or middleware. The MojeID Identity service provided by CZ.NIC is authorized by the Czech Ministry of the Interior for accessing online government services and all eIDAS compliant online services in the EU.
The only FIDO Security Key on the market today to meet the requirements of high assurance of eIDAS and work across every user device is the GoTrust Idem Key. “We were delighted to find exactly the FIDO Security Key we required to get eIDAS High accreditation,” commented Ondřej Filip, CEO at CZ.NIC.
About GoTrustID Inc.
GoTrustID Inc. (GoTrust) is the pioneer company providing passwordless multi-factor authentication (MFA) platform for an employee’s everyday items: phone, a USB Key, or their smart badge. Our mission is to make simple & secure login anywhere and anytime. With every authenticator and server certified by FIDO, GoTrust Authentication Platform makes every employee become their own ID, having effortless login to their computer, corporate systems, and cloud services. GoTrustID has nineteen international patents granted, including six US patents.
About CZ.NIC
CZ.NIC, z. s. p. o., is an interest association of legal entities founded in 1998. The association currently has 117 members. One key activity of the association is the operation of the domain name registry for the .CZ domain. Another is the provision of the MojeID service supporting technologies and projects beneficial to the Internet infrastructure in the Czech Republic.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220726005092/en/
Contact information
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom